Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Predictors of Sinonasal Improvement After Highly Effective Modulator Therapy in Adults with Cystic Fibrosis.
Beswick DM, Liu CM, Overdevest JB, Zemke A, Khatiwada A, Gudis DA, Miller JE, Kimple A, Tervo JP, DiMango E, Goralski JL, Keating C, Senior B, Stapleton AL, Eshaghian PH, Mace JC, Markarian K, Alt JA, Bodner TE, Chowdhury NI, Getz AE, Hwang PH, Khanwalker A, Lee JT, Li DA, Norris M, Nayak JV, Owens C, Patel ZM, Poch K, Schlosser RJ, Smith KA, Smith TL, Soler ZM, Suh JD, Turner GA, Wang MB, Saavedra MT, Taylor Cousar JL. Beswick DM, et al. Among authors: goralski jl. Laryngoscope. 2024 Apr 18. doi: 10.1002/lary.31438. Online ahead of print. Laryngoscope. 2024. PMID: 38634358
Association between unplanned pregnancies and maternal exacerbations in cystic fibrosis.
Peng G, Taylor-Cousar JL, Lee M, Keller A, West NE, Kazmerski TM, Goralski JL, Aitken ML, Roe AH, Hadjiliadis D, Uluer A, Flume PA, Mody S, Bray LA, Jain R. Peng G, et al. Among authors: goralski jl. J Cyst Fibros. 2023 Sep;22(5):796-803. doi: 10.1016/j.jcf.2023.03.020. Epub 2023 Apr 5. J Cyst Fibros. 2023. PMID: 37029015
Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2-5 Years with Cystic Fibrosis and at Least One F508del Allele.
Goralski JL, Hoppe JE, Mall MA, McColley SA, McKone E, Ramsey B, Rayment JH, Robinson P, Stehling F, Taylor-Cousar JL, Tullis E, Ahluwalia N, Chin A, Chu C, Lu M, Niu T, Weinstock T, Ratjen F, Rosenfeld M. Goralski JL, et al. Am J Respir Crit Care Med. 2023 Jul 1;208(1):59-67. doi: 10.1164/rccm.202301-0084OC. Am J Respir Crit Care Med. 2023. PMID: 36921081 Free PMC article.
Non-respiratory health-related quality of life in people with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor.
Fajac I, Daines C, Durieu I, Goralski JL, Heijerman H, Knoop C, Majoor C, Bruinsma BG, Moskowitz S, Prieto-Centurion V, Van Brunt K, Zhang Y, Quittner A. Fajac I, et al. Among authors: goralski jl. J Cyst Fibros. 2023 Jan;22(1):119-123. doi: 10.1016/j.jcf.2022.08.018. Epub 2022 Sep 14. J Cyst Fibros. 2023. PMID: 36114142 Free article. Clinical Trial.
CFTR bearing variant p.Phe312del exhibits function inconsistent with phenotype and negligible response to ivacaftor.
Raraigh KS, Paul KC, Goralski JL, Worthington EN, Faino AV, Sciortino S, Wang Y, Aksit MA, Ling H, Osorio DL, Onchiri FM, Patel SU, Merlo CA, Montemayor K, Gibson RL, West NE, Thakerar A, Bridges RJ, Sheppard DN, Sharma N, Cutting GR. Raraigh KS, et al. Among authors: goralski jl. JCI Insight. 2022 Mar 22;7(6):e148841. doi: 10.1172/jci.insight.148841. JCI Insight. 2022. PMID: 35315358 Free PMC article.
Elexacaftor-Tezacaftor- Ivacaftor improves sinonasal outcomes in cystic fibrosis.
Stapleton AL, Kimple AJ, Goralski JL, Nouraie SM, Branstetter BF, Shaffer AD, Pilewski JM, Senior BA, Lee SE, Zemke AC. Stapleton AL, et al. Among authors: goralski jl. J Cyst Fibros. 2022 Sep;21(5):792-799. doi: 10.1016/j.jcf.2022.03.002. Epub 2022 Mar 14. J Cyst Fibros. 2022. PMID: 35300931 Free PMC article.
33 results